Breaking News Instant updates and real-time market news.

CCXI

ChemoCentryx

$8.06

0.13 (1.64%)

07:13
11/26/19
11/26
07:13
11/26/19
07:13

ChemoCentryx price target raised to $40 from $23 at H.C. Wainwright

H.C. Wainwright analyst Edward White raised his price target for ChemoCentryx to $40 from $23 after the company announced positive results from the Phase 3 Advocate study. The analyst increased his probability of success for avacopan to 70% from 30% and keeps a Buy rating on ChemoCentryx shares.

CCXI ChemoCentryx
$8.06

0.13 (1.64%)

09/12/19
JPMS
09/12/19
UPGRADE
Target $14
JPMS
Overweight
ChemoCentryx upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded ChemoCentryx to Overweight from Neutral with a price target of $14, down from $16. The analyst sees a favorable risk/reward profile at current share levels.
09/12/19
JPMS
09/12/19
UPGRADE
Target $14
JPMS
Overweight
JPMorgan upgrades ChemoCentryx to Overweight ahead of Phase 3 readout
JPMorgan analyst Anupam Rama upgraded ChemoCentryx to Overweight from Neutral with a price target of $14, down from $16. Following a round of key opinion leader and physician discussions, the analyst believes the Phase 3 Advocate study of avacopan in associated vasculitis has a high probability of success. The share pressure dating back to the spring has created a favorable risk/reward scenario for shares of ChemoCentryx ahead of the Phase 3 results, Rama tells investors in a research note. The analyst expects the readout in the mid-to-late Q4 timeframe.
10/15/19
JPMS
10/15/19
NO CHANGE
JPMS
Overweight
ChemoCentryx can rally 110% on positive Advocate results, says JPMorgan
JPMorgan analyst Anupam Rama says shares ChemoCentryx can rally 90%-110% on positive Phase 3 Advocate trial results of avacopan in ANCA-associated vasculitis, expected in Q4. The analyst sees share downside of 45%-80% on negative results. Rama continues to believe that Advocate has a high probability of success and that the totality of data will be key for adoption. He keeps an Overweight rating on ChemoCentryx shares.
11/26/19
PIPR
11/26/19
NO CHANGE
Target $54
PIPR
Overweight
ChemoCentryx price target raised to $54 from $17 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for ChemoCentryx to $54 from $17 after the company announced positive Phase III Advocate data on avacopan in ANCA-associated vasculitis. The stock in premarket trading is up 312%, or $25.14, to $33.20. The trial met both primary endpoints of non-inferior Birmingham Vasculitis Activity Score remission compared to steroids at 26 and 52 weeks, Tenthoff tells investors in a research note. Based on these results, he believes avacopan could replace steroids in standard-of-care treatment of ANCA-associated vasculitis and potentially more broadly. He reiterates an Overweight rating on ChemoCentryx shares.

TODAY'S FREE FLY STORIES

CRWD

Crowdstrike

$53.00

-2.04 (-3.71%)

07:45
12/06/19
12/06
07:45
12/06/19
07:45
Recommendations
Crowdstrike analyst commentary  »

Crowdstrike's Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

07:45
12/06/19
12/06
07:45
12/06/19
07:45
General news
Treasury Market Outlook: stocks and bonds are modestly firmer »

Treasury Market Outlook:…

DESP

Despegar.com

$12.42

0.19 (1.55%)

07:44
12/06/19
12/06
07:44
12/06/19
07:44
Conference/Events
Despegar.com to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 17

    Dec

MAKSY

Marks & Spencer

$0.00

(0.00%)

07:41
12/06/19
12/06
07:41
12/06/19
07:41
Upgrade
Marks & Spencer rating change  »

Marks & Spencer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKTA

Okta

$119.18

-2.64 (-2.17%)

07:40
12/06/19
12/06
07:40
12/06/19
07:40
Recommendations
Okta analyst commentary  »

Okta results reaffirm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

ULTA

Ulta Beauty

$236.09

-3.27 (-1.37%)

07:39
12/06/19
12/06
07:39
12/06/19
07:39
Recommendations
Ulta Beauty analyst commentary  »

Ulta Beauty quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Mar

SAGE

Sage Therapeutics

$60.11

-89.11 (-59.72%)

07:39
12/06/19
12/06
07:39
12/06/19
07:39
Recommendations
Sage Therapeutics analyst commentary  »

Raymond James does not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$17.73

0.18 (1.03%)

07:38
12/06/19
12/06
07:38
12/06/19
07:38
Conference/Events
Nuance to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

COO

Cooper Companies

$313.10

1 (0.32%)

07:36
12/06/19
12/06
07:36
12/06/19
07:36
Recommendations
Cooper Companies analyst commentary  »

Cooper Companies price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

SLG

SL Green Realty

$85.75

-0.08 (-0.09%)

07:35
12/06/19
12/06
07:35
12/06/19
07:35
Hot Stocks
SL Green Realty announces $500M increase to share repurchase program »

SL Green Realty announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DLTR

Dollar Tree

$90.80

1.47 (1.65%)

, BUD

AB InBev

$78.61

-0.76 (-0.96%)

07:35
12/06/19
12/06
07:35
12/06/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

DLTR

Dollar Tree

$90.80

1.47 (1.65%)

BUD

AB InBev

$78.61

-0.76 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

07:35
12/06/19
12/06
07:35
12/06/19
07:35
General news
FX Update: A firmer yen and a rallying New Zealand dollar were the main shows »

FX Update: A firmer yen…

RST

Rosetta Stone

$15.23

0.09 (0.59%)

07:34
12/06/19
12/06
07:34
12/06/19
07:34
Initiation
Rosetta Stone initiated  »

Rosetta Stone initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

SLG

SL Green Realty

$85.75

-0.08 (-0.09%)

07:34
12/06/19
12/06
07:34
12/06/19
07:34
Hot Stocks
SL Green Realty increases quarterly dividend 4.1% to 88.5c per share »

SL Green Realty reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

UNFI

United Natural Foods

$9.43

-0.35 (-3.58%)

07:33
12/06/19
12/06
07:33
12/06/19
07:33
Hot Stocks
United Natural Foods to sell 13 Shoppers Food & Pharmacy stores »

United Natural Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 18

    Dec

EW

Edwards Lifesciences

$242.87

-3.41 (-1.38%)

07:33
12/06/19
12/06
07:33
12/06/19
07:33
Recommendations
Edwards Lifesciences analyst commentary  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZM

Zoom Video

$69.73

-0.22 (-0.31%)

07:33
12/06/19
12/06
07:33
12/06/19
07:33
Recommendations
Zoom Video analyst commentary  »

Zoom Video price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

ONTX

Onconova

$0.30

-0.0148 (-4.77%)

07:32
12/06/19
12/06
07:32
12/06/19
07:32
Hot Stocks
Onconova, Inceptua announce Pre-approval Access collaboration for rigosertib »

Onconova Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$53.79

-0.235 (-0.44%)

07:32
12/06/19
12/06
07:32
12/06/19
07:32
Hot Stocks
Biohaven's troriluzole successfully advances past interim futility analysis »

Biohaven announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$60.11

-89.11 (-59.72%)

07:30
12/06/19
12/06
07:30
12/06/19
07:30
Recommendations
Sage Therapeutics analyst commentary  »

Sage Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRIS

Curis

$1.86

0.045 (2.48%)

07:29
12/06/19
12/06
07:29
12/06/19
07:29
Hot Stocks
Curis provides updated results from Phase 1 dose escalation study of CA-4948 »

Curis announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

XNCR

Xencor

$40.63

0.05 (0.12%)

07:29
12/06/19
12/06
07:29
12/06/19
07:29
Conference/Events
Xencor to host analyst & investor meeting »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

MRVL

Marvell

$23.44

-0.48 (-2.01%)

07:27
12/06/19
12/06
07:27
12/06/19
07:27
Recommendations
Marvell analyst commentary  »

Marvell price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 06

    Jan

SON

Sonoco

$59.91

-0.04 (-0.07%)

07:25
12/06/19
12/06
07:25
12/06/19
07:25
Conference/Events
Sonoco to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 09

    Dec

  • 13

    Dec

RRC

Range Resources

$3.59

0.01 (0.28%)

07:23
12/06/19
12/06
07:23
12/06/19
07:23
Downgrade
Range Resources rating change  »

Range Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.